Ivonescimab meets key goal in biliary tract cancer trial, partners report
Akeso and Summit Therapeutics announced that their bispecific antibody ivonescimab achieved a primary endpoint in a Phase 3 study for biliary tract cancer, marking a success beyond lung cancer. The trial was conducted exclusively in China, and the companies touted the result as a significant milestone for the drug candidate.
Related stories
Zipalertinib succeeds in Phase 3 trial for EGFR-mutant lung cancer, challenging Rybrevant · Cancer research
Personalized mRNA vaccine hits Phase 3 goal in Merck-Moderna trial · Cancer research
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Akeso, Summit hail ivonescimab's biliary tract cancer win in China-only Phase 3 trial.” Browse more stories.